Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma

• Published in: Modern pathology 2022-09, Vol.35 (9), p.1181-1192
• Main Authors: Xiang, Chan, Ji, Chunyu, Cai, Yiran, Teng, Haohua, Wang, Yulu, Zhao, Ruiying, Shang, Zhanxian, Guo, Lianying, Chen, Shengnan, Lizaso, Analyn, Lin, Jing, Wang, Haozhe, Li, Bing, Zhang, Zhou, Zhao, Jikai, Wei, Jinzhi, Liu, Jiaxin, Zhu, Lei, Fang, Wentao, Han, Yuchen
• Format: Article
• Language: English
• Subjects: 45/23; 631/67/1612/1350; 631/67/395; 631/67/69; Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adenocarcinoma - surgery; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - surgery; Cancer; Carcinogenesis; Epidermal growth factor receptors; ErbB-2 protein; Gene frequency; Genes; Humans; Insertion; Kinases; Laboratory Medicine; Lesions; Low frequency; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Lungs; Medicine; Medicine & Public Health; Missense mutation; Mutants; Mutation; Mutation rates; Next-generation sequencing; Pathology; Patients; Proto-Oncogene Proteins B-raf - genetics; Retrospective Studies; Tumor suppressor genes; Tumorigenesis; Tumors
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/s41379-022-01076-w

Lung adenocarcinoma (LUAD) is a heterogeneous disease. Our study aimed to understand the unique molecular features of preinvasive to invasive LUAD subtypes. We retrospectively analyzed the clinical, histopathological, and molecular data of 3,254 Chinese patients with preinvasive lesions (n = 252), minimally invasive adenocarcinomas (n = 479), and invasive LUAD (n = 2,523). Molecular data were elucidated using a targeted 68-gene next-generation sequencing panel. Our findings revealed four preinvasive lesion-predominant gene mutations, including MAP2K1 insertion-deletions (indels), BRAF non-V600E kinase mutations, and exon 20 insertions (20ins) in both EGFR and ERBB2, which we referred to as mutations enriched in AIS (MEA). The detection rate of MEA in invasive tumors was relatively lower. MAP2K1 missense mutations, which were likely passenger mutations, co-occurred with oncogenic driver mutations, while small indels were mutually exclusive from other genes regardless of the invasion level. BRAF non-V600E kinase-mutant invasive adenocarcinomas (IAC) had significantly higher mutation rates in tumor suppressor genes but lower frequency of co-occurring oncogenic driver mutations than non-kinase-mutant IAC, suggesting the potential oncogenic activity of BRAF non-V600E kinase mutations albeit weaker than BRAF V600E. Moreover, similar to the extremely low frequency of MAP2K1 indels in IAC, BRAF non-V600E kinase domain mutations co-occurring with TSC1 mutations were exclusively found in preinvasive lesions. Compared with EGFR L858R and exon 19 deletion, patients with preinvasive lesions harboring 20ins in either EGFR or ERBB2 were significantly younger, while those with IAC had similar age. Furthermore, our study demonstrated distinct mutational features for subtypes of oncogene mutations favored by different invasion patterns in adenocarcinomas. In conclusion, our data demonstrate distinct mutational features between preinvasive lesions and invasive tumors with MEA, suggesting the involvement of MEA in the early stages of tumorigenesis. Further pre-clinical studies are required to establish the role of these genes in the malignant transformation of LUAD.